194 related articles for article (PubMed ID: 34159558)
1. Subcutaneously Administered Anti-TNFs for the Treatment of Ulcerative Colitis: A Retrospective, Propensity Score-Matched, US Health Claims Analysis.
Stewart MJ; Bessissow T; Gregor J; Hazel M; In TSH; Karra K; Dajnowiec D; Williamson M; Sattin B
Adv Ther; 2021 Jul; 38(7):4115-4129. PubMed ID: 34159558
[TBL] [Abstract][Full Text] [Related]
2. Living with ulcerative colitis in Germany: a retrospective analysis of dose escalation, concomitant treatment use and healthcare costs.
Dignass A; Waller J; Cappelleri JC; Modesto I; Kisser A; Dietz L; DiBonaventura M; Wood R; May M; Libutzki B; Bargo D
J Med Econ; 2020 Apr; 23(4):415-427. PubMed ID: 31858853
[No Abstract] [Full Text] [Related]
3. Comparative effectiveness and safety of infliximab and adalimumab in patients with ulcerative colitis.
Singh S; Heien HC; Sangaralingham LR; Schilz SR; Kappelman MD; Shah ND; Loftus EV
Aliment Pharmacol Ther; 2016 May; 43(9):994-1003. PubMed ID: 26991059
[TBL] [Abstract][Full Text] [Related]
4. Real-World Incidence of Suboptimal Response to Anti-Tumor Necrosis Factor Therapy for Ulcerative Colitis: A Nationwide Population-Based Study.
Shin JY; Park HM; Lee MY; Jeon JY; Yoo HJ; Ye BD
Gut Liver; 2021 Nov; 15(6):867-877. PubMed ID: 33785664
[TBL] [Abstract][Full Text] [Related]
5. Retrospective Database Analysis: Dose Escalation and Adherence in Patients Initiating Biologics for Ulcerative Colitis.
Long MD; Cohen RD; Smith TW; DiBonaventura M; Gruben D; Bargo D; Salese L; Quirk D
Dig Dis; 2022; 40(5):553-564. PubMed ID: 34879378
[TBL] [Abstract][Full Text] [Related]
6. Treatment persistence and colectomy-free outcomes in patients with ulcerative colitis receiving golimumab or adalimumab: a UK experience.
Hoque S; Puenpatom A; Boccaletti S; Green C; Black CM; Roberts J; Rajkovic I; Milligan G
BMJ Open Gastroenterol; 2020 Nov; 7(1):. PubMed ID: 33199269
[TBL] [Abstract][Full Text] [Related]
7. Using Healthcare Databases to Replicate Trial Findings for Supplemental Indications: Adalimumab in Patients with Ulcerative Colitis.
Spoendlin J; Desai RJ; Franklin JM; Glynn RJ; Payne E; Schneeweiss S
Clin Pharmacol Ther; 2020 Oct; 108(4):874-884. PubMed ID: 32320482
[TBL] [Abstract][Full Text] [Related]
8. A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysis.
Renna S; Mocciaro F; Ventimiglia M; Orlando R; Macaluso FS; Cappello M; Fries W; Mendolaro M; Privitera AC; Ferracane C; Pisana V; Magnano A; Pluchino D; Inserra G; Scarpulla G; Garufi S; Carroccio A; Siringo S; Di Mitri R; Cottone M; Orlando A
Dig Liver Dis; 2018 Dec; 50(12):1292-1298. PubMed ID: 30007516
[TBL] [Abstract][Full Text] [Related]
9. Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States.
Sandborn WJ; Sakuraba A; Wang A; Macaulay D; Reichmann W; Wang S; Chao J; Skup M
Curr Med Res Opin; 2016 Jul; 32(7):1233-41. PubMed ID: 26986449
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Real-World Outcomes of Infliximab versus Adalimumab in Biologic-Naïve Korean Patients with Ulcerative Colitis: A Population-Based Study.
Han M; Jung YS; Cheon JH; Park S
Yonsei Med J; 2020 Jan; 61(1):48-55. PubMed ID: 31887799
[TBL] [Abstract][Full Text] [Related]
11. Efficacies of first and second tumor necrosis factor inhibitors in refractory ulcerative colitis patients in real-world practice.
Marutani Y; Mizoshita T; Sugiyama T; Togawa S; Katano T; Yamada T; Hirata Y; Kimura Y; Miyaki T; Inoue Y; Suzuki E; Sasaki M; Kataoka H
Indian J Gastroenterol; 2020 Dec; 39(6):565-575. PubMed ID: 33106991
[TBL] [Abstract][Full Text] [Related]
12. Treatment persistence and maintenance dose titration among ulcerative colitis patients on biologics: a pooled study of three United States claim databases.
Sah J; Teeple A; Muser E; Gutierrez C; Dassopoulos T
Curr Med Res Opin; 2022 Jul; 38(7):1093-1101. PubMed ID: 35475385
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Infliximab and Adalimumab in Biologic-Naive Patients With Ulcerative Colitis: A Nationwide Danish Cohort Study.
Singh S; Andersen NN; Andersson M; Loftus EV; Jess T
Clin Gastroenterol Hepatol; 2017 Aug; 15(8):1218-1225.e7. PubMed ID: 27913244
[TBL] [Abstract][Full Text] [Related]
14. A propensity score weighted comparison of Vedolizumab, Adalimumab, and Golimumab in patients with ulcerative colitis.
Macaluso FS; Ventimiglia M; Fries W; Viola A; Cappello M; Scrivo B; Magnano A; Pluchino D; Camilleri S; Garufi S; Mitri RD; Mocciaro F; Magrì G; Ferracane C; Citrano M; Graziano F; Bertolami C; Renna S; Orlando R; Rizzuto G; Cottone M; Orlando A;
Dig Liver Dis; 2020 Dec; 52(12):1461-1466. PubMed ID: 32601033
[TBL] [Abstract][Full Text] [Related]
15. Similar Clinical Outcomes of Early and Late Anti-TNF Initiation for Ulcerative Colitis: A Nationwide Population-Based Study.
Han M; Jung YS; Cheon JH; Park S
Yonsei Med J; 2020 May; 61(5):382-390. PubMed ID: 32390361
[TBL] [Abstract][Full Text] [Related]
16. Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study.
Jung YS; Han M; Park S; Cheon JH
Dig Dis Sci; 2020 May; 65(5):1436-1444. PubMed ID: 31677070
[TBL] [Abstract][Full Text] [Related]
17. Real-world Effectiveness of Advanced Therapies Among Patients With Moderate to Severe Ulcerative Colitis in the United States.
Long MD; Smith TW; Dibonaventura M; Gruben D; Bargo D; Salese L; Quirk D
Inflamm Bowel Dis; 2020 May; 26(6):941-948. PubMed ID: 31560046
[TBL] [Abstract][Full Text] [Related]
18. Dose-escalation of adalimumab, golimumab or ustekinumab in inflammatory bowel diseases: characterization and implications in real-life clinical practice.
Ylisaukko-Oja T; Puttonen M; Jokelainen J; Koivusalo M; Tamminen K; Torvinen S; Voutilainen M
Scand J Gastroenterol; 2022 Apr; 57(4):415-423. PubMed ID: 34927504
[TBL] [Abstract][Full Text] [Related]
19. Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.
Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
J Clin Gastroenterol; 2015 Sep; 49(8):675-82. PubMed ID: 25389599
[TBL] [Abstract][Full Text] [Related]
20. Golimumab for moderately to severely active ulcerative colitis.
Kedia S; Ahuja V; Makharia GK
Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1273-82. PubMed ID: 27498886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]